6
Oct
2026

Prestige BioPharma Ltd

Exhibitor at CPHI Milan 2026 stand 5D114, Integrated Pharma
About Us

PRESTIGE BIOPHARMA (PBP) is an innovative biopharma company specializing in the development and manufacturing of innovative antibody-based drugs and biosimilars. Tuznue™, our trastuzumab biosimilar, received EU approval in Sept 2024. Our innovative pipelines include a mAb targeting pancreatic cancer in clinical trials, and solid tumor targeted mAb in preclinical development. We have a robust portfolio of biosimilars, targeting the next wave of patent expiries, and open to partnerships and collaborations.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    Singapore
  • On CPHI since:
    2018
  • Employees:
    250 - 499
Company types
Biopharmaceutical company
Contract Service
Innovation cluster
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Biopharmaceutical
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Milan 2026
  • 6 Oct 2026 - 8 Oct 2026
  • Fiera Milano, Italy
  • Visit us at stand 5D114, Integrated Pharma

Products Featured at CPHI Milan 2026

  • Tuznue™ (Trastuzumab biosimilar)

    Product Tuznue™ (Trastuzumab biosimilar)

    Tuznue™ is a biosimilar of Herceptin® (trastuzumab), developed to offer a more cost-effective therapeutic alternative for patients. It maintains comparable efficacy and safety profiles to the original branded medication. Tuznue™ is indicated for the treatment of patients with HER2-positive metastatic breas...
  • HD204 (Bevacizumab biosimilar)

    Product HD204 (Bevacizumab biosimilar)

    This is a biosimilar candidate of bevacizumab (Avastin®). Bevacizumab is used to treat many different types of cancer (often as first-line therapy) including metastatic colorectal cancer, non-small-cell lung cancer (NSCLC), renal cell cancer, ovarian cancer and metastatic breast cancer. Global Phase 3 ...
  • PBP1502 (Adalimumab biosimilar)

    Product PBP1502 (Adalimumab biosimilar)

    This is a biosimilar candidate of adalimumab (Humira®). Adalimumab is used to treat many inflammatory conditions in adults, such as rheumatoid arthritis. Phase 1 IND approved in Spain and the study is currently ongoing.

  • PBP1510 (INN: Ulenistamab)

    Product PBP1510 (INN: Ulenistamab)

    PBP1510 is a first-in-class monoclonal antibody drug developed by Prestige Biopharma Limited against pancreatic adenocarcinoma up-regulated factor (PAUF), a protein that is overexpressed in pancreatic adenocarcinoma. PAUF is involved in promoting tumor growth, invasion, and metastasis, in the evasion o...